Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tsubota LaboratoryTSE:4890 +2.49%61 Receivables Turnover is 2.75 as of Mar. 2026. GuruFocus rates TSE:4890 with a GF Score™ of 61/100 and a GF Value™ of 円82.12 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Tsubota Laboratory ranks worse than 96.92% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tsubota Laboratory's Revenue for the
six
months ended in Mar. 2026 was 円97.2 Mil. Tsubota Laboratory's average Accounts Receivable for the
six
months ended in Mar. 2026 was 円35.4 Mil.
Hence, Tsubota Laboratory's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.75.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tsubota Laboratory Receivables Turnover Related Terms
Tsubota Laboratory Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tsubota Laboratory's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4890 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Tsubota Laboratory's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsubota Laboratory Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tsubota Laboratory's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsubota Laboratory (TSE:4890) has a Receivables Turnover of 2.75 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tsubota Laboratory and its competitors. According to the industry distribution chart, Tsubota Laboratory ranks #787 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 96.9%.
Is Tsubota Laboratory's Receivables Turnover too high?
Tsubota Laboratory's current Receivables Turnover is 2.75. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Tsubota Laboratory's value of 2.75 is 50.1% below this industry median. Based on the distribution chart, Tsubota Laboratory ranks #787 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tsubota Laboratory has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Tsubota Laboratory ranks #787 out of 812 companies for Receivables Turnover. This places Tsubota Laboratory in the lower half of its industry. The industry median Receivables Turnover is 5.51. Tsubota Laboratory's value of 2.75 is 50.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsubota Laboratory's current Receivables Turnover of 2.75 is 50.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tsubota Laboratory and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsubota Laboratory's current Receivables Turnover is 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円82.12, compared to a current price of 円247.00 — trading 200.8% above its estimated fair value. The current Receivables Turnover is 2.75 and 50.1% below the Medical Devices & Instruments industry median of 5.51. Tsubota Laboratory's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current Receivables Turnover is 2.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?
Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued.
The current stock price of 円247.00 is trading 200.8% above its estimated GF Value™ of 円82.12.
GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.
Key valuation signals for TSE:4890:
Receivables Turnover: 2.75
GF Value™: 円82.12 vs. price of 円247.00 (200.8% above fair value)
Industry Position: 50.1% below the Medical Devices & Instruments median (#787 of 812)
No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
61GF Score
Get the complete analysis for TSE:4890
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4890 has been successfully added to your 
